U.S. Stock News

IMAX (IMAX) is back in the spotlight as it prepares an exclusive theatrical debut for Baz Luhrmann’s Elvis Presley concert documentary, alongside two-day 50th anniversary IMAX screenings of The Who’s rock opera film Tommy. See our latest analysis for IMAX. At a share price of US$37.80, IMAX has logged a 6.78% 3 month share price return and a 38.87% 1 year total shareholder return, and recent box office events and premium content partnerships appear to be contributing to gradually building...

Viper Energy (NasdaqGS:VNOM) is acquiring Sitio Royalties, expanding its royalty footprint in US shale. The company plans to sell its non Permian assets, sharpening its focus on its core basin. Management is working on integrating Sitio's assets into Viper's no capex royalty model. Analysts are highlighting how the combined royalty portfolio could affect future cash generation and distributions. Viper Energy, trading at $44.61, has seen its share price move 20.8% over the past month and...

Pacific Ridge Capital Partners has fully exited its position in AXT (NasdaqGS:AXTI), removing a major institutional shareholder from the register. The divestment comes shortly after AXT reported a revenue turnaround at a time when the company is facing headwinds from China related export restrictions. This shift in ownership occurs as AXT continues to operate under heightened policy and trade scrutiny that directly affects parts of its business. AXT, which supplies compound semiconductor...

Constellium FY 2025 Results: Revenue Steady, Earnings Volatile Constellium (CSTM) just posted another quarter of mixed numbers, with Q3 2025 revenue at US$2.2b, basic EPS of US$0.63 and net income of US$88m. The latest trailing twelve month figures show revenue of about US$8.0b and EPS of US$0.80 alongside a net margin of 1.4% compared to 1.8% the prior year. Over recent quarters, the company has seen revenue move from US$1.8b in Q3 2024 to US$2.2b in Q3 2025. Quarterly EPS has swung from a...

CBIZ (NYSE:CBZ) has authorized a new share repurchase program for up to 5,000,000 shares. The new authorization follows the expiration of the company’s previous buyback plan. The announcement reflects a fresh capital allocation decision focused on returning capital to shareholders. CBIZ provides professional services, including financial, insurance and advisory solutions, which tie closely to corporate spending, regulatory needs and risk management. When a company in this space refreshes...

If you are wondering whether Texas Pacific Land is attractively priced or simply expensive for what you get, you are in the right place to unpack what the current share price might be implying. The stock closed at US$440.71, with returns of 6.6% over 7 days, 30.6% over 30 days, 47.9% year to date, while the 1 year return stands at a 5.3% decline and the 3 year and 5 year returns are 129.4% and 268.9% respectively. Recent news around Texas Pacific Land has focused on its position within the...

Kontoor Brands (NYSE:KTB) has adopted an Executive Severance Plan, formalizing protections for senior leadership in certain termination scenarios. The board also approved a quarterly dividend, continuing the return of capital to shareholders. These moves come as the company’s shares trade at $67.85, with a mixed return profile across different time frames. Kontoor Brands is pairing governance changes with ongoing shareholder payouts at a time when the stock has a varied track record...

Why CureVac's latest trial milestone matters for shareholders CureVac (CVAC) has completed a Phase 1 clinical study for its CVGBM mRNA based brain cancer vaccine in patients with surgically resected glioblastoma or astrocytoma, marking a key early checkpoint for its oncology pipeline. See our latest analysis for CureVac. The completion of the CVGBM Phase 1 study comes after a sharp 14.32% 1 day share price decline and a 19.18% 7 day share price return. However, CureVac’s year to date share...

In February 2026, Parsons Corporation reported fourth-quarter and full-year 2025 results showing lower sales but slightly higher net income year-on-year, while also issuing 2026 revenue guidance of US$6.5 billion to US$6.8 billion and securing several new U.S. defense and security contracts, including a US$125 million Army research award and a US$91 million State Department security extension. Shortly after these mixed results and contract wins, Parsons’ Sealing Technologies unit received an...

Biogen (BIIB) is back in focus after its latest quarterly earnings, where management highlighted contributions from newer drugs and analysts flagged the product portfolio as an important driver of current investor interest. See our latest analysis for Biogen. Biogen’s recent earnings release, upcoming leadership changes, and conference appearances have coincided with a 30 day share price return of 18.07% and a 1 year total shareholder return of 42.03%. This suggests momentum has strengthened...

Earlier this month, research firm Leerink Partners downgraded BioNTech SE’s rating after a strong rally, even as the company secured FDA Fast Track designation for its cancer candidate BNT113 and its Supervisory Board appointed Kylie Jimenez as Chief People Officer to support its oncology ambitions. This combination of regulatory momentum for BNT113 and a leadership hire aligned with BioNTech’s goal of becoming a multi-product oncology company by 2030 underscores how the business is...

Jones Lang LaSalle (JLL) has put up a busy FY 2025 so far, with Q3 revenue at US$6.5b and basic EPS of US$4.71, alongside trailing 12 month revenue of US$25.3b and EPS of US$13.31 that captures the broader earnings cycle. Over recent quarters the company has seen revenue move from US$5.7b and EPS of US$1.17 in Q1 2025 to US$6.3b and EPS of US$2.37 in Q2, and then to US$6.5b and EPS of US$4.71 in Q3, with a 32.1% earnings increase over the past year setting the backdrop for a business where...

If you are wondering whether Intuitive Surgical at around US$500.76 a share still offers value or has run ahead of itself, you are not alone. The stock has had a mixed run, with a 0.9% gain over the last 7 days, a 6.4% decline over the past month, a 10.9% decline year to date, and a 17.7% decline over the past year, while still showing a 114.4% return over 3 years and 98.0% over 5 years. Recent coverage has focused on Intuitive Surgical's position as a key player in robotic assisted surgery...

The Hartford’s board recently declared a US$0.60 per-share common dividend payable on April 2 and a US$375 Series G preferred dividend payable on May 15, reinforcing its ongoing role in property and casualty insurance, employee benefits, and mutual funds. Amid analyst forecasts for softer near-term revenue, the combination of fresh dividends and faster book-value growth highlights management’s emphasis on capital return backed by strengthening assets. Next, we’ll explore how this new...

Halozyme Therapeutics (HALO) closed out FY 2025 with fourth quarter revenue of US$451.8 million and a basic EPS loss of US$1.20, compared with Q4 2024 revenue of US$298.0 million and basic EPS of US$1.08. Over the past year, the company has seen quarterly revenue move from US$290.1 million in Q3 2024 to US$354.3 million in Q3 2025, while basic EPS shifted from US$1.08 to US$1.49 over the same quarters, creating a mixed picture for margins as investors digest the latest numbers. See our full...

Glaukos (GKOS) has just posted its FY 2025 numbers with Q4 revenue of US$143.1 million and a basic EPS loss of US$2.32, alongside a trailing twelve month revenue line of US$507.4 million and a basic EPS loss of US$3.28. Over recent quarters, the company has seen revenue move from US$96.7 million in Q3 2024 to US$105.5 million in Q4 2024 and then to US$143.1 million in Q4 2025, while quarterly basic EPS losses shifted from US$0.39 in Q3 2024 to US$0.60 in Q4 2024 and US$2.32 in Q4 2025. For...

If you are wondering whether Ciena's share price still lines up with its underlying value, you are not alone. This article will walk through what the current market price might be implying. Ciena closed at US$310.96, with returns of 4.6% over the last 7 days, 27.7% over 30 days, 26.4% year to date, 257.2% over 1 year and a very large gain over 3 and 5 years. Recent headlines around Ciena have kept attention on the stock, as investors weigh what the current price means for long term...

AtriCure (ATRC) just posted its FY 2025 numbers with Q4 revenue of US$140.5 million and basic EPS of US$0.04 on net income of US$1.8 million, while on a trailing twelve month basis the company remains loss making with basic EPS at US$0.24 and net income of US$11.4 million. The company has seen quarterly revenue move from US$124.3 million in Q4 2024 to US$140.5 million in Q4 2025. Over the same periods, basic EPS shifted from a loss of US$0.33 to a small profit of US$0.04. This sets up a story...

Entegris (ENTG) is back in focus after fourth quarter results topped analyst forecasts. Management pointed to strength in advanced node semiconductor applications and solid demand for CMP consumables and liquid filtration products. See our latest analysis for Entegris. At a share price of US$131.89, Entegris has logged a 91.7% 90 day share price return and a 47.26% year to date share price return. The 1 year total shareholder return of 22.65% points to momentum that has recently...

Comparor has announced the launch of its AI-powered shopping assistant, a tool designed to streamline the online shopping process by offering instant product recommendations and real-time price comparisons across multiple retailers. This solution leverages artificial intelligence to process natural language requests and deliver optimized shopping options, helping users save time and make more informed purchasing decisions. As an emerging trend in e-commerce, AI-enabled tools like Comparor’s...

Artivion, Inc.'s ( NYSE:AORT ) earnings announcement last week was disappointing for investors, despite the decent...

Investors signalled that they were pleased with Cognex Corporation's ( NASDAQ:CGNX ) most recent earnings report. This...

W. R. Berkley Corporation ( NYSE:WRB ) is about to trade ex-dividend in the next three days. The ex-dividend date is...

It looks like Johnson & Johnson ( NYSE:JNJ ) is about to go ex-dividend in the next 4 days. The ex-dividend date occurs...